Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Core Viewpoint - Salarius Pharmaceuticals has adjourned its 2025 Annual Meeting of Stockholders to solicit additional votes due to insufficient quorum, with the meeting reconvened for December 31, 2025 [1][2]. Company Information - Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing new treatment options for cancer patients, with two drug candidates in its portfolio: seclidemstat and SP-3164 [9]. - Seclidemstat is being studied in a Phase 1/2 clinical trial for hematologic cancers at MD Anderson Cancer Center, targeting myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) [9]. - SP-3164 is an oral small molecule protein degrader currently in the IND stage [9]. - The company has received financial support for its drug candidates from various organizations, including the National Pediatric Cancer Foundation and the Cancer Prevention and Research Institute of Texas [9]. Meeting Details - The required quorum for the Annual Meeting is 34% of outstanding shares, but only approximately 30% of shares were represented at the time of adjournment [2][3]. - Stockholders eligible to vote are encouraged to do so via the Internet or phone, with the record date for voting remaining October 24, 2025 [3][4]. - The reconvened meeting will be held virtually, allowing stockholders to participate online [2]. Subsidiary Information - Salarius' subsidiary, Decoy Therapeutics Inc., is a preclinical-stage biotechnology company utilizing machine learning and AI tools to develop peptide conjugate drug candidates targeting unmet medical needs, particularly in respiratory viruses and gastrointestinal cancers [7]. - Decoy has secured financing from institutional investors and various funding programs, including the Massachusetts Life Sciences Seed Fund and the Google AI startup program [7].